Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

A nose-to-brain drug delivery approach leverages neural pathways to achieve high brain exposure with low systemic levels, offering a non-invasive alternative to transporter-based BBB strategies for ...

THE electrical conductivity of an electrolyte is determined by its ion concentration. The effect of dispersed solid particles of a comparatively low conductance, such as proteins, can be taken into ...

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

Quince Therapeutics Inc. is scrapping work with dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for patients with ataxia-telangiectasia (A-T), and Boral analyst Jason ...